University of Yaounde Report issue

Academic/Hospital Phase 2 Phase 3 Phase 4
Founded: Yaounde Cameroon (1962)

Organization Overview

First Clinical Trial
2003
NCT00146718
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Alternative names

Biotechnology Center (BTC), University of Yaounde I, Cameroon | Biotechnology Centre, University of Yaounde I | Central Hospital, Yaounde, Cameroon | Centre for Food and Nutrition Research, Yaounde | CN NGANOU-GNINDJIO, MD, MSc | Consultant Endocrinologist, National Obesity Centre/ Senior Lecturer, University of Yaounde 1, Cameroon and Newcastle University, UK | Faculty of Medicine and Bio-Medical Sciences, University of Yaoundé | Faculty of Medicine and Biomedical Sciences University of Yaounde (Cameroon) | Faculty of Medicine and Biomedical Sciences, University of Yaounde I | Gateway Health Alliances / University of Yaounde | Hôpital Central de Yaoundé et Université de Yaoundé 1 | Infectious diseases department, Central Hospital, Yaounde, Cameroon | International diabetes federation/ Director, National Obesity Centre, Yaounde Central Hospital, Cameroon | Laboratory for Public Health Biotechnology, University of Yaounde I | Laboratory of Nutrition and Nutritional Biochemistry (LNNB), Department of Biochemistry, University of Yaounde I, Yaounde, Cameroon | National Obesity Centre, Yaounde Central Hospital, Cameroon | University of Yaounde 1 | University of Yaounde 1, Cameroon | University of Yaounde I | Yaounde Central Hospital | Yaounde Central Hospital and University of Yaounde 1

Active Ingredients

Drugs in Phase 4 Trials (32)

amlodipine (norvasc) (2 trials)

amodiaquine (camoquin) (5 trials)

artemether (3 trials)

artesunate (6 trials)

azithromycin (zithromax) (1 trial)

bisoprolol (zebeta) (1 trial)

calcium (1 trial)

dihydroartemisinin (2 trials)

doxycycline (vibramycin) (1 trial)

empagliflozin (jardiance) (1 trial)

ferric polymaltose hydroxide (1 trial)

ginger (1 trial)

hydrochlorothiazide (esidrix) (1 trial)

hydroxychloroquine (plaquenil) (1 trial)

indapamide (lozol) (1 trial)

iron sucrose (venofer) (1 trial)

liraglutide (victoza) (1 trial)

losartan (cozaar) (1 trial)

lumefantrine (Coartem) (5 trials)

mebendazole (vermox) (1 trial)

mefloquine (lariam) (1 trial)

moringa oleifera (1 trial)

perindopril (aceon) (4 trials)

piperaquine (2 trials)

propanolol (1 trial)

rivaroxaban (xarelto) (1 trial)

spironolactone (aldactone) (1 trial)

stevia (2 trials)

valsartan (diovan) (1 trial)

vildagliptin (1 trial)

vitamin d3 (1 trial)

zofenopril (1 trial)

Drugs in Phase 3 Trials (14)

abacavir (ziagen) (1 trial)

annona muricata (1 trial)

atazanavir (reyataz) (1 trial)

coartem (2 trials)

darunavir (prezista) (3 trials)

didanosine (videx) (1 trial)

emtricitabine (emtriva) (1 trial)

lamivudine (epivir) (1 trial)

lopinavir (Kaletra) (3 trials)

pyrimethamine (daraprim) (1 trial)

quinine (qualaquin) (1 trial)

ritonavir (Norvir) (3 trials)

sulfadoxine (1 trial)

tenofovir (viread) (1 trial)

Drugs in Phase 2 Trials (1)

lepticore (1 trial)

Drugs in Other Trials (10)

arthrospira platensis (1 trial)

cissus (1 trial)

fluconazole (diflucan) (1 trial)

insulin human (humulin) (1 trial)

irvingia (1 trial)

irvingia gabonensis (1 trial)

proalgazyme (2 trials)

soybean (1 trial)

spirulina (1 trial)

vitamin a (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Acquired Immunodeficiency Syndrome (Phase 3)

Anemia, Iron-Deficiency (Phase 4)

Diabetes Mellitus (Phase 4)

Diabetes Mellitus, Type 2 (Phase 4)

Heart Failure (Phase 4)

HIV Infections (Phase 3)

Hyperglycemia (Phase 2)

Hyperlipidemias (Phase 2)

Hypersensitivity (Phase 4)

Hypertension (Phase 4)

Hyperthyroidism (Phase 4)

Insulin Resistance (Phase 4)

Malaria (Phase 4)

Malaria, Falciparum (Phase 4)

Metabolic Syndrome (Phase 2)

Weight Loss (Phase 2)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 38
  • # of Trial APIs: 57